Evaluation of the Tolerance to Natural Killer Cell Injection in Multiple Myeloma Patients Eligible for Autologous Transplantation

A Phase I/II Single Center Study to Assess Tolerability and Feasibility of Infusions of Allogeneic ExpandedNatural Killer (NK) Cells in Patients Treated with Autologous Stem Cell Transplantation for MultipleMyeloma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140818018842N46

Enrollment

Registered

2025-02-19

Start date

2025-02-19

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma. Multiple myeloma

Interventions

Intervention 1: Intervention group: Patients receiving natural lethal cell on day 7 after transplantation.(In these patients, natural killer cells will be injected at a dose of 1*10^7 cells per kilogr

Eligibility

Sex/Gender

All

Age

18 Years to 71 Years

Inclusion criteria

Inclusion criteria: Patients with Multiple Milom Multiples over 18 years of age Candidate of AutoHSCT (First Time) Carnovsky Function> 70%

Exclusion criteria

Exclusion criteria: Previous AutoHSCT history A history of autoimmune disease

Design outcomes

Primary

Measure	Time frame
Tolerance of natural lethal cells in the Autologous transplant. Timepoint: Days 7 and 14 and 28 after transplantation and every three months. Method of measurement: Fever (thermometer) Bacterial and fungal infections (blood and tissue) serum and urine protein electrophoresis (laboratory).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Salek

Tehran University of Medical Sciences

mohammad_salek@yahoo.com+98 21 8490 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026